Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 194

1.

Lack of pharmacokinetic interactions between argatroban and warfarin.

Brown PM, Hursting MJ.

Am J Health Syst Pharm. 2002 Nov 1;59(21):2078-83.

PMID:
12434720
2.

Investigation of the interaction between argatroban and acetaminophen, lidocaine, or digoxin.

Inglis AM, Sheth SB, Hursting MJ, Tenero DM, Graham AM, DiCicco RA.

Am J Health Syst Pharm. 2002 Jul 1;59(13):1258-66.

PMID:
12116891
3.

Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban.

Tran JQ, Di Cicco RA, Sheth SB, Tucci M, Peng L, Jorkasky DK, Hursting MJ, Benincosa LJ.

J Clin Pharmacol. 1999 May;39(5):513-9.

PMID:
10234600
5.

Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin.

Ragueneau-Majlessi I, Levy RH, Meyerhoff C.

Epilepsy Res. 2001 Nov;47(1-2):55-63.

PMID:
11673021
6.
7.

Absence of a pharmacokinetic interaction between etanercept and warfarin.

Zhou H, Patat A, Parks V, Buckwalter M, Metzger D, Korth-Bradley J.

J Clin Pharmacol. 2004 May;44(5):543-50.

PMID:
15102876
8.

Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin.

Wade M, Hunt TL, Lai AA.

J Cardiovasc Pharmacol. 2003 Jun;41(6):908-15.

PMID:
12775969
9.

Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects.

Swan SK, St Peter JV, Lambrecht LJ, Hursting MJ.

Pharmacotherapy. 2000 Jul;20(7):756-70.

PMID:
10907966
10.

The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin.

Tiseo PJ, Foley K, Friedhoff LT.

Br J Clin Pharmacol. 1998 Nov;46 Suppl 1:45-50.

11.

Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin.

Schwartz JI, Dunbar S, Yuan J, Li S, Gipson A, Rosko K, Johnson-Levonas AO, Lasseter KC, Addy C, Stoch AS, Wagner JA.

Adv Ther. 2008 Nov;25(11):1175-90. doi: 10.1007/s12325-008-0116-9.

PMID:
18989636
12.

Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.

He YL, Sabo R, Riviere GJ, Sunkara G, Leon S, Ligueros-Saylan M, Rosenberg M, Dole WP, Howard D.

Curr Med Res Opin. 2007 May;23(5):1131-8.

PMID:
17519080
13.
14.
15.

Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin.

Faaij RA, Burggraaf J, Schoemaker RC, Van Amsterdam RG, Cohen AF.

Br J Clin Pharmacol. 2002 Sep;54(3):304-8.

16.

Ciprofloxacin prolonged-release tablets do not affect warfarin pharmacokinetics and pharmacodynamics.

Washington C, Hou SY, Hughes NC, Campanella C, Berner B.

J Clin Pharmacol. 2007 Oct;47(10):1320-6. Epub 2007 Aug 27.

PMID:
17724088
17.

Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin.

Schwartz JI, Liu F, Stroh M, Gipson A, Johnson-Levonas AO, Lasseter KC, Lai E, Wagner JA.

Am J Ther. 2009 May-Jun;16(3):215-23. doi: 10.1097/MJT.0b013e31818f9c68.

PMID:
19454860
18.

Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.

Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ.

Br J Clin Pharmacol. 2004 May;57(5):592-9. Erratum in: Br J Clin Pharmacol. 2004 Jul;58(1):102.

19.

The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole.

Uno T, Sugimoto K, Sugawara K, Tateishi T.

Ther Drug Monit. 2008 Jun;30(3):276-81. doi: 10.1097/FTD.0b013e31816e2d8e.

PMID:
18520598
20.

Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.

Malhotra B, Alvey C, Gong J, Li X, Duczynski G, Gandelman K.

Br J Clin Pharmacol. 2011 Aug;72(2):257-62. doi: 10.1111/j.1365-2125.2011.03989.x.

Items per page

Supplemental Content

Write to the Help Desk